<p>Chimeric antigen receptor T-cell (CAR-T) therapy is a novel cancer treatment modality associated with unique treatment considerations and associated toxicities and therefore is administered at select hospitals. As a result, hematology trainees have variable exposure to CAR-T management. The purpose of this study was to systematically develop a national electronic learning module (ELM) to facilitate CAR-T education among Canadian hematology trainees. First, a survey-based needs assessment was conducted. Participants indicated moderate to significant benefit from further education on CAR-T therapy. They also identified key content areas of educational need and key priorities for a CAR-T ELM. Based on this data, an ELM was developed using the Articulate 360 platform, with input from CAR-T content experts. Semi-structured focus groups were then conducted to pilot the draft ELM, and qualitative thematic analysis identified consistent themes in positive and negative feedback. The ELM was further iteratively revised based on this feedback, and the final ELM product has been made available online as an open-access resource. The results of this study demonstrate the successful development of a CAR-T e-learning resource to fulfill an educational gap for a novel cancer therapy. Future steps include quantitative evaluation of the educational efficacy of the ELM.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Development of an Electronic Learning Module for CAR-T Education in Canadian Hematology Residents

  • Grace Zhang,
  • Audrey Dong,
  • Kylie Lepic,
  • Gwynivere Amber Davies,
  • Amaris Karin Balitsky

摘要

Chimeric antigen receptor T-cell (CAR-T) therapy is a novel cancer treatment modality associated with unique treatment considerations and associated toxicities and therefore is administered at select hospitals. As a result, hematology trainees have variable exposure to CAR-T management. The purpose of this study was to systematically develop a national electronic learning module (ELM) to facilitate CAR-T education among Canadian hematology trainees. First, a survey-based needs assessment was conducted. Participants indicated moderate to significant benefit from further education on CAR-T therapy. They also identified key content areas of educational need and key priorities for a CAR-T ELM. Based on this data, an ELM was developed using the Articulate 360 platform, with input from CAR-T content experts. Semi-structured focus groups were then conducted to pilot the draft ELM, and qualitative thematic analysis identified consistent themes in positive and negative feedback. The ELM was further iteratively revised based on this feedback, and the final ELM product has been made available online as an open-access resource. The results of this study demonstrate the successful development of a CAR-T e-learning resource to fulfill an educational gap for a novel cancer therapy. Future steps include quantitative evaluation of the educational efficacy of the ELM.